시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 임상 차세대 시퀀싱(NGS) 데이터 분석 시장 보고서(2025년)
Clinical Next-Generation Sequencing (NGS) Data Analysis Global Market Report 2025
상품코드 : 1824618
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,469,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,350,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,232,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

임상 차세대 시퀀싱(NGS) 데이터 분석 시장 규모는 앞으로 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 18.8%를 나타내 82억 4,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 리퀴드 바이옵시 기술의 채용 증가, 데이터 분석에 있어서의 인공지능의 통합, 정밀의료 이니셔티브의 확대, 신규 시퀀싱 기술의 출현, 집단 유전체학 이니셔티브에 대한 주목 증가에 기인하는 것으로 예측됩니다. 예측 기간의 주요 동향으로는 동반자 진단의 성장, 분산형 검사 모델의 상승, 클라우드 기반 솔루션 이용 증가, 비침습적 출생 전 검사에서 NGS 용도 확대, 데이터 분석을 위한 표준화 프로토콜 개발 등이 있습니다.

향후 5년간의 성장률 18.8%라고 하는 예측은 이 시장의 전회 예측으로부터의 0.8%라고 하는 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 부과는 핀란드와 덴마크에서 수입되는 클라우드 기반 바이오인포매틱스 플랫폼 및 변형 해석 소프트웨어의 비용을 증가시키고 정밀 종양학의 도입을 늦추거나 분석 비용을 증가시킬 수 있기 때문에 미국의 유전체 의료를 혼란시킬 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

임상 차세대 시퀀싱(NGS) 데이터 분석 시장은 맞춤형 의료에 대한 수요 증가에 힘입어 성장할 전망입니다. 개인의 유전적, 환경적, 라이프스타일적 요인에 맞춘 맞춤형 의료는 유전체 기술, 질병의 복잡화, 치료 성적의 향상, 헬스케어 비용의 상승에 의해 주목받고 있습니다. 차세대 시퀀싱(NGS) 데이터 분석은 개인화된 의료에서 매우 중요한 역할을 하며, 여러 유전자의 신속하고 정확한 시퀀싱을 용이하게 함으로써 개인의 유전자 프로파일에 대한 이해를 깊게 합니다. 예를 들어, 2022년 10월의 데이터에서는 상당한 수의 유전자 검사 제품과 개별화 의약품이 보고되어, 개별화 의약품이 신약 승인의 주목할 부분을 차지했기 때문에 맞춤형 의료의 도입을 추진하는 데 있어서 NGS 데이터 분석이 불가결한 역할을 담당한 것을 알 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Clinical next-generation sequencing (NGS) data analysis is the interpretation of genetic information acquired through advanced sequencing technologies within a clinical context. These technologies enable the rapid and cost-effective sequencing of large DNA or RNA samples, allowing for the identification of genetic variations associated with diseases or conditions. This analytical process is essential for comprehending the genetic underpinnings of diseases, supporting personalized medicine approaches, and guiding clinical decision-making.

The main types of solutions and services in clinical next-generation sequencing (NGS) data analysis encompass NGS data analysis tools, NGS data analysis and sequencing services, and NGS storage, management, and cloud computing platforms. NGS data analysis tools are software applications designed to interpret and process the vast amount of data generated through NGS technologies. Leveraging various sequencing technologies such as sequencing by synthesis (SBS), nanopore sequencing, and single-molecule real-time (SMRT) sequencing, these tools find applications in diagnostics, drug discovery, medical research, and other domains. End-users of these tools span hospitals, clinics, academic institutes, research centers, biotechnology companies, and life science technology vendors.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The clinical next-generation sequencing (NGS) data analysis market research report is one of a series of new reports from The Business Research Company that provides clinical next-generation sequencing (NGS) data analysis market statistics, including clinical next-generation sequencing (NGS) data analysis industry global market size, regional shares, competitors with a clinical next-generation sequencing (NGS) data analysis market share, detailed clinical next-generation sequencing (NGS) data analysis market segments, market trends and opportunities, and any further data you may need to thrive in the clinical next-generation sequencing (NGS) data analysis industry. This clinical next-generation sequencing (NGS) data analysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical next-generation sequencing (ngs) data analysis market size has grown exponentially in recent years. It will grow from $3.43 billion in 2024 to $4.14 billion in 2025 at a compound annual growth rate (CAGR) of 20.5%. The growth in the historic period can be attributed to research advancements in genomics, declining sequencing costs, growing demand for personalized medicine, expanding applications in clinical diagnostics, increasing prevalence of genetic diseases.

The clinical next-generation sequencing (ngs) data analysis market size is expected to see rapid growth in the next few years. It will grow to $8.24 billion in 2029 at a compound annual growth rate (CAGR) of 18.8%. The growth in the forecast period can be attributed to rising adoption of liquid biopsy techniques, integration of artificial intelligence in data analysis, expansion of precision medicine initiatives, emergence of novel sequencing technologies, increasing focus on population genomics initiatives. Major trends in the forecast period include growth of companion diagnostics, rise of decentralized testing models, increasing use of cloud-based solutions, expansion of NGS applications in non-invasive prenatal testing, development of standardized protocols for data interpretation.

The forecast of 18.8% growth over the next five years reflects a modest reduction of 0.8% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. genomic medicine by increasing costs for cloud-based bioinformatics platforms and variant interpretation software imported from Finland and Denmark, potentially slowing precision oncology implementation and raising analysis costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The clinical next-generation sequencing data analysis market is poised for growth, propelled by the rising demand for personalized medicines. Personalized medicine, tailored to individual genetic, environmental, and lifestyle factors, gains prominence due to genomic technologies, increasing disease complexity, improved treatment outcomes, and escalating healthcare costs. Next-generation sequencing (NGS) data analysis plays a pivotal role in personalized medicine, facilitating rapid and accurate sequencing of multiple genes, thereby enhancing understanding of an individual's genetic profile. For example, data from October 2022 reports a significant number of genetic testing products and personalized medicines, with personalized medicines accounting for a notable portion of new drug approvals, underlining the integral role of NGS data analysis in driving personalized medicine adoption.

Key players in the clinical NGS data analysis market are innovating to meet burgeoning demands for genomic analysis accuracy. Advanced solutions such as the NextSeq 2000 Sequencing System represent significant developments in this realm. This system comprises integrated hardware and software components designed to streamline DNA sequencing processes, offering precise nucleotide sequencing within DNA molecules. For instance, Illumina Inc.'s September 2022 launch of the NovaSeq X Series introduces a paradigm shift in production-scale sequencing, boasting enhanced speed, power, and sustainability. Leveraging innovative technology such as XLEAP-SBS chemistry and ultra-high density flow cells, the NovaSeq X Series offers substantially increased throughput and sequencing accuracy, meeting the escalating demands for genomic analysis.

In January 2023, QIAGEN NV, a Germany-based provider of molecular testing solutions, acquired Verogen Inc. for $150 million. The acquisition aims to strengthen QIAGEN's molecular testing and forensic genomics offerings by incorporating Verogen's next-generation sequencing (NGS) technology, which enhances capabilities in genetic analysis. Verogen Inc., a US-based company, specializes in NGS solutions focused on human identification (Human ID) and forensic applications.

Major companies operating in the clinical next-generation sequencing (NGS) data analysis market are Roche Diagnostics, Thermo Fisher Scientific Inc., Eurofins Scientific, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen, BGI Group, 10x Genomics, Genomic Health, Oxford Nanopore Technologies PLC., Pacific Biosciences of California Inc., Sophia Genetics, Genewiz, Partek Inc., DNAnexus, BioNano Genomics, PierianDx, GENAPSYS, Nugen Technologies, DNAStar Inc., Swift Biosciences, Basepair, BioDatomics, Congenica Ltd., Theragen Etex Inc., Golden Helix Inc.

North America was the largest region in the clinical next-generation sequencing (NGS) data analysis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clinical next-generation sequencing (NGS) data analysis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the clinical next-generation sequencing (NGS) data analysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The clinical next-generation sequencing data analysis market consists of revenues earned by entities by providing services such as data preprocessing, alignment, variable calling, annotation, prioritization, interpretation, and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The clinical next-generation sequencing data analysis market also includes sales of software tools, platforms, and pre-processing tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Clinical Next-Generation Sequencing (NGS) Data Analysis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on clinical next-generation sequencing (ngs) data analysis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for clinical next-generation sequencing (ngs) data analysis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The clinical next-generation sequencing (ngs) data analysis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Clinical Next-Generation Sequencing (NGS) Data Analysis Market Characteristics

3. Clinical Next-Generation Sequencing (NGS) Data Analysis Market Trends And Strategies

4. Clinical Next-Generation Sequencing (NGS) Data Analysis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Clinical Next-Generation Sequencing (NGS) Data Analysis Growth Analysis And Strategic Analysis Framework

6. Clinical Next-Generation Sequencing (NGS) Data Analysis Market Segmentation

7. Clinical Next-Generation Sequencing (NGS) Data Analysis Market Regional And Country Analysis

8. Asia-Pacific Clinical Next-Generation Sequencing (NGS) Data Analysis Market

9. China Clinical Next-Generation Sequencing (NGS) Data Analysis Market

10. India Clinical Next-Generation Sequencing (NGS) Data Analysis Market

11. Japan Clinical Next-Generation Sequencing (NGS) Data Analysis Market

12. Australia Clinical Next-Generation Sequencing (NGS) Data Analysis Market

13. Indonesia Clinical Next-Generation Sequencing (NGS) Data Analysis Market

14. South Korea Clinical Next-Generation Sequencing (NGS) Data Analysis Market

15. Western Europe Clinical Next-Generation Sequencing (NGS) Data Analysis Market

16. UK Clinical Next-Generation Sequencing (NGS) Data Analysis Market

17. Germany Clinical Next-Generation Sequencing (NGS) Data Analysis Market

18. France Clinical Next-Generation Sequencing (NGS) Data Analysis Market

19. Italy Clinical Next-Generation Sequencing (NGS) Data Analysis Market

20. Spain Clinical Next-Generation Sequencing (NGS) Data Analysis Market

21. Eastern Europe Clinical Next-Generation Sequencing (NGS) Data Analysis Market

22. Russia Clinical Next-Generation Sequencing (NGS) Data Analysis Market

23. North America Clinical Next-Generation Sequencing (NGS) Data Analysis Market

24. USA Clinical Next-Generation Sequencing (NGS) Data Analysis Market

25. Canada Clinical Next-Generation Sequencing (NGS) Data Analysis Market

26. South America Clinical Next-Generation Sequencing (NGS) Data Analysis Market

27. Brazil Clinical Next-Generation Sequencing (NGS) Data Analysis Market

28. Middle East Clinical Next-Generation Sequencing (NGS) Data Analysis Market

29. Africa Clinical Next-Generation Sequencing (NGS) Data Analysis Market

30. Clinical Next-Generation Sequencing (NGS) Data Analysis Market Competitive Landscape And Company Profiles

31. Clinical Next-Generation Sequencing (NGS) Data Analysis Market Other Major And Innovative Companies

32. Global Clinical Next-Generation Sequencing (NGS) Data Analysis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Clinical Next-Generation Sequencing (NGS) Data Analysis Market

34. Recent Developments In The Clinical Next-Generation Sequencing (NGS) Data Analysis Market

35. Clinical Next-Generation Sequencing (NGS) Data Analysis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기